Mechanisms of altered fatty acid and phospholipid levels in hyperhomocysteinemia

Future Lipidology

Volumn 4, Issue 2, 2009, Pages 159-166

  Devlin, Angela M ^a   Green, Tim J ^b  

^a UNIVERSITY OF BRITISH COLUMBIA   (Canada)

^b UNIVERSITY OF BRITISH COLUMBIA   (Canada)

Author keywords

Arachidonic acid; Docosahexaenoic acid; Fatty acid; Hyperhomocysteinemia; Liver; Methionine; Methylation; Mice; Phosphatidylcholine; Phosphatidylethanolamine

Indexed keywords

5 METHYLTETRAHYDROFOLIC ACID; BETAINE HOMOCYSTEINE METHYLTRANSFERASE; CITICOLINE; FATTY ACID; HOMOCYSTEINE; LIPOPROTEIN; METHIONINE; PHOSPHATIDYLCHOLINE; PHOSPHOLIPID; POLYUNSATURATED FATTY ACID; VERY LOW DENSITY LIPOPROTEIN;

CHOLESTEROL BLOOD LEVEL; ENDOTHELIAL DYSFUNCTION; FATTY ACID METABOLISM; HUMAN; HYPERHOMOCYSTEINEMIA; LIPID LIVER LEVEL; LIPOPROTEIN BLOOD LEVEL; LIPOPROTEIN SECRETION; NONHUMAN; PATHOGENESIS; PHOSPHOLIPID BLOOD LEVEL; PHOSPHOLIPID METABOLISM; PHOSPHOLIPID SYNTHESIS; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; REVIEW; VASCULAR ENDOTHELIUM;

MUS;

EID: 67249093241     PISSN: 17460875     EISSN: None     Source Type: Journal    
DOI: 10.2217/CLP.09.3     Document Type: Review

References (52)

1. Homocysteine Studies Collaboration: Homocysteine and risk of ischemic heart disease and stroke: a meta-analysis. JAMA 288, 2015-2022 (2002).
2. Seshadri S, Beiser A, Selhub J et al.: Plasma homocysteine as a risk factor for dementia and Alzheimer's disease. N. Engl. J. Med. 346, 476-483 (2002).
3. van Meurs B, Dhonukshe-Rutten RA, Pluijm SM et al.: Homocysteine levels and the risk of osteoporotic fracture. N. Engl. J. Med. 350,2033-2041 (2004).
4. McLean RR, Jacques PF, Selhub J et al.: Homocysteine as a predictive factor for hip fracture in older persons. N. Engl. J. Med. 350, 2042-2049 (2004).
5. 12, homocysteine, and the MTHFR 677C->T polymorphism in anxiety and depression: The Hordaland Homocysteine Study. Arch. Gen. Psychiatry 60, 618-626 (2003).
6. Bellamy MF, McDowell IF, Ramsey MW et al.: Hyperhomocysteinemia after an oral methionine load acutely impairs endothelial function in healthy adults. Circulation 98, 1848-1852 (1998).
7. Lentz SR, Sobey CG, Piegors DJ et al.: Vascular dysfunction in monkeys with diet-induced hyperhomocyst(e)inemia. J. Clin. Invest. 98, 24-29 (1996).
8. Dayal S, Bottiglieri T, Arning E et al.: Endothelial dysfunction and elevation of S-adenosylhomocysteine in cystathionine β-synthase-deficient mice. Circ. Res. 88, 1203-1209 (2001).
9. Eberhardt RT, Forgione MA, Cap A et al.: Endothelial dysfunction in a murine model of mild hyperhomocyst(e)inemia. J. Clin. Invest. 106, 483-491 (2000).
10. Devlin AM, Arning E, Bottiglieri T, Faraci FM, Rozen R, Lentz SR: Effect of Mthfr genotype on diet-induced hyperhomo-cysteinemia and vascular function in mice. Blood 103, 2624-2629 (2004).
11. Dayal S, Devlin AM, McCaw RB et al.: Cerebral vascular dysfunction in methionine synthase-deficient mice. Circulation 112, 737-744 (2005).
12. Hamel E, Nicolakakis N, Aboulkassim T, Ongali B, Tong XK: Oxidative stress and cerebrovascular dysfunction in mouse models of Alzheimer's disease. Exp. Physiol. 93, 116-120 (2008).
13. Austin RC, Lentz SR, Werstuck GH: Role of hyperhomocysteinemia in endothelial dysfunction and atherothrombotic disease. Cell Death Differ. 11 Suppl 1, S56-S64 (2004).
14. Finkelstein JD: Methionine metabolism in mammals. J. Nutr. Biochem. 1, 228-237 (1990).
15. Yao ZM, Vance DE: The active synthesis of phosphatidylcholine is required for very low density lipoprotein secretion from rat hepatocytes. J. Biol. Chem. 263, 2998-3004 (1988).
16. Yao ZM, Vance DE: Head group specificity in the requirement of phosphatidylcholine biosynthesis for very low density lipoprotein secretion from cultured hepatocytes. J. Biol. Chem. 264, 11373-11380 (1989).
17. Node K, Huo Y, Ruan X et al.: Anti-inflammatory Properties of cytochrome P450 epoxygenase-derived eicosanoids. Science 285, 1276-1279 (1999).
18. Fleming I, Busse R: Endothelium-derived epoxyeicosatrienoic acids and vascular function. Hypertension 47, 629-633 (2006).
19. De Vriese AS, Blom HJ, Heil SG et al.: Endothelium-derived hyperpolarizing factor-mediated renal vasodilatory response is impaired during acute and chronic hyperhomocysteinemia. Circulation 109, 2331-2336 (2004).
20. Yi P, Melnyk S, Pogribna M, Pogribny IP, Hine RJ, James SJ: Increase in plasma homocysteine associated with parallel increases in plasma S-adenosylhomocysteine and lymphocyte DNA hypomethylation. J. Biol. Chem. 275, 29318-29323 (2000).
21. Castro R, Rivera I, Struys EA et al.: Increased homocysteine and S-adenosylhomocysteine concentrations and DNA hypomethylation in vascular disease. Clin. Chem. 49, 1292-1296 (2003).
22. Chen Z, Karaplis AC, Ackerman SL et al.: Mice deficient in methylenetetrahydrofolate reductase exhibit hyperhomocysteinemia and decreased methylation capacity, with neuropathology and aortic lipid deposition. Hum. Mol. Genet. 10, 433-443 (2001).
23. Devlin AM, Bottiglieri T, Domann FE, Lentz SR: Tissue-specific changes in H19 methylation and expression in mice with hyperhomocysteinemia. J. Biol. Chem. 280, 25506-25511 (2005).
24. Devlin AM, Singh R, Wade RE, Innis SM, Bottiglieri T, Lentz SR: Hypermethylation of Fads2 and altered hepatic fatty acid and phospholipid metabolism in mice with hyperhomocysteinemia. J. Biol. Chem. 282, 37082-37090 (2007).
25. Li Z, Vance DE: Phosphatidylcholine and choline homeostasis. J. Lipid Res. 49, 1187-1194 (2008).
26. Noga AA, Stead LM, Zhao Y, Brosnan ME, Brosnan JT, Vance DE: Plasma homocysteine is regulated by phospholipid methylation. J. Biol. Chem. 278, 5952-5955 (2003).
27. Jacobs RL, Devlin C, Tabas I, Vance DE: Targeted deletion of hepatic ctp:phosphocholine cytidylyltransferase-α in mice decreases plasma high density and very low density lipoproteins. J. Biol. Chem. 279, 47402-47410 (2004).
28. Jacobs RL, Stead LM, Devlin C et al.: Physiological regulation of phospholipid methylation alters plasma homocysteine in mice. J. Biol. Chem. 280, 28299-28305 (2005).
29. Watanabe M, Osada J, Aratani Y et al.: Mice deficient in cystathionine β-synthase: animal models for mild and severe homocyst(e)inemia. Proc. Natl Acad. Sci. USA 92, 1585-1589 (1995).
30. Namekata K, Enokido Y, Ishii I, Nagai Y, Harada T, Kimura H: Abnormal lipid metabolism in cystathionine β-synthase-deficient mice, an animal model for hyperhomocysteinemia. J. Biol. Chem. 279, 52961-52969 (2004).
31. Troen AM, Chao WH, Crivello NA et al.: Cognitive impairment in folate-deficient rats corresponds to depleted brain phosphatidylcholine and is prevented by dietary methionine without lowering plasma homocysteine. J. Nutr. 138, 2502-2509 (2008).
32. Selley ML: A metabolic link between S-adenosylhomocysteine and polyunsaturated fatty acid metabolism in Alzheimer's disease. Neurobiol. Aging 28, 1834-1839 (2007).
33. Pritchard PH, Chiang PK, Cantoni GL, Vance DE: Inhibition of phosphatidyl-ethanolamine N-methylation by 3-deazaadenosine stimulates the synthesis of phosphatidylcholine via the CDP-choline pathway. J. Biol. Chem. 257, 6362-6367 (1982).
34. Baric I, Fumic K, Glenn B et al.: S-adenosylhomocysteine hydrolase deficiency in a human: a genetic disorder of methionine metabolism. Proc. Natl Acad. Sci. USA 101, 4234-4239 (2004).
35. Cui Z, Vance JE, Chen MH, Voelker DR, Vance DE: Cloning and expression of a novel phosphatidylethanolamine N-methyltransferase. A specific biochemical and cytological marker for a unique membrane fraction in rat liver. J. Biol. Chem. 268, 16655-16663 (1993).
36. Guan Z-Z, Wang Y-N, Xiao K-Q, Hu P-S, Liu J-L: Activity of phosphatidylethanolamine-N-methyltransferase in brain affected by Alzheimers disease. Neurochem. Int. 34, 41-47 (1999).
37. da Costa KA, Kozyreva OG, Song J, Galanko JA, Fischer LM, Zeisel SH: Common genetic polymorphisms affect the human requirement for the nutrient choline. FASEB J. 20, 1336-1344 (2006).
38. Werstuck GH, Lentz SR, Dayal S et al.: Homocysteine-induced endoplasmic reticulum stress causes dysregulation of the cholesterol and triglyceride biosynthetic pathways. J. Clin. Invest. 107, 1263-1273 (2001).
39. Noga AA, Vance DE: A Gender-specific role for phosphatidylethanolamine N-methyltransferase-derived phosphatidylcholine in the regulation of plasma high density and very low density lipoproteins in mice. J. Biol. Chem. 278, 21851-21859 (2003).
40. Mikael LG, Genest J Jr, Rozen R: Elevated homocysteine reduces apolipoprotein A-I expression in hyperhomocysteinemic mice and in males with coronary artery disease. Circ. Res. 98, 564-571 (2006).
41. Liao D, Tan H, Hui R et al.: Hyperhomocysteinemia decreases circulating high-density lipoprotein by inhibiting apolipoprotein A-I protein synthesis and enhancing HDL cholesterol clearance. Circ. Res. 99, 598-606 (2006).
42. Stampfer MJ, Malinow MR, Willet WC et al.: A prospective study of plasma homocyst(e)ine and risk of myocardial infarction in U.S. physicians. JAMA 268, 877-881 (1992).
43. Ridgway ND, Vance DE: Specificity of rat hepatic phosphatidylethanolamine N-methyltransferase for molecular species of diacyl phosphatidylethanolamine. J. Biol. Chem. 263, 16856-16863 (1988).
44. DeLong CJ, Shen YJ, Thomas MJ, Cui Z: Molecular distinction of phosphatidylcholine synthesis between the CDP-choline pathway and phosphatidylethanolamine methylation pathway. J. Biol. Chem. 274,29683-29688 (1999).
45. Watkins SM, Zhu X, Zeisel SH: Phosphatidylethanolamine-N-methyltransferase activity and dietary choline regulate liver-plasma lipid flux and essential fatty acid metabolism in mice. J. Nutr. 133, 3386-3391 (2003).
46. Li D, Mann N, Sinclair A: A significant inverse relationship between concentrations of plasma homocysteine and phospholipid docosahexaenoic acid in healthy male subjects. Lipids 41, 85-89 (2006).
47. Assies J, Lok A, Bockting CL et al.: Fatty acids and homocysteine levels in patients with recurrent depression: an explorative pilot study. Prostaglandins Leukot. Essent. Fatty Acids 70, 349-356 (2004).
48. Assies J, Pouwer F: One-carbon metabolism and depression. Br. J. Psychiatry 193, 344-2008).
49. Crowe FL, Skeaff CM, McMahon JA, Williams SM, Green TJ: Lowering plasma homocysteine concentrations of older men and women with folate, vitamin B-12, and vitamin b-6 does not affect the proportion of (n-3) long chain polyunsaturated fatty acids in plasma phosphatidylcholine. J. Nutr. 138, 551-555 (2008).
50. Schaeffer L, Gohlke H, Muller M et al.: Common genetic variants of the FADS1 FADS2 gene cluster and their reconstructed haplotypes are associated with the fatty acid composition in phospholipids. Hum. Mol. Genet. 15, 1745-1756 (2006).
51. Nakamura MT, Nara TY: Structure, function, and dietary regulation of δ6, δ5, and Δ9 desaturases. Annu. Rev. Nutr. 24, 345-376 (2004).
52. Miller RR, Leanza CM, Phillips EE, Blacquire KD: Homocysteine-induced changes in brain membrane composition correlate with increased brain caspase-3 activities and reduced chick embryo viability. Comp. Biochem. Physiol. B, Biochem. Mol. Biol. 136, 521-532 (2003).